Skip to main content
SpringerLink
Log in

Applications of Dynamic Contrast-Enhanced MRI in Oncology Drug Development

  • Chapter
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Baba Y, Furusawa M, Murakami R, Yokoyama T, Sakamoto Y, Nishimura R, Yamashita Y, Takahashi M, Ishikawa T (1997) Role of dynamic MRI in the evaluation of head and neck cancers treated with radiation therapy. Int J Radiat Oncol Biol Phys 37:783–787

    Article  PubMed  Google Scholar 

  • Barentsz JO, Berger-Hartog O, Witjes JA, Hulsbergen-van der Kaa C, Oosterhof GO, VanderLaak JA, Kondacki H, Ruijs SH (1998) Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791–797

    PubMed  Google Scholar 

  • Blasberg RG, Roelcke U, Weinreich R, Beattie B, von Ammon K, Yonekawa Y, Landolt H, Guenther I, Crompton NE, Vontobel P, Missimer J, Maguire RP, Koziorowski J, Knust EJ, Finn RD, Leenders KL (2000) Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 60:624–635

    PubMed  Google Scholar 

  • Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, Toyoshima S, Kuroki S, Ohno S (1996) Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200:639–649

    PubMed  Google Scholar 

  • Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A (1997) Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 7:461–464

    PubMed  Google Scholar 

  • Checkley D, Tessier J, Kendrew J et al (2003) Dynamic contrast-enhanced MRI as a marker of biological effect: a study of a human prostate tumor xenograft treated with the VEGF signaling inhibitor ZD6474. Br J Cancer 89:1889–1895.

    Article  PubMed  Google Scholar 

  • Cooper RA, Carrington BM, Loncaster JA et al. (2000) Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57:53–59

    Article  PubMed  Google Scholar 

  • Cristofanilli M, Charnsangavej C, Hortobagyi GN (2002) Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov 1:415–426

    Article  PubMed  Google Scholar 

  • Devries AF, Griebel J, Kremser C, Judmaier W, Gneiting T, Kreczy A, Ofner D, Pfeiffer KP, Brix G, Lukas P (2001) Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 61:2513–2516

    PubMed  Google Scholar 

  • Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408–3416

    PubMed  Google Scholar 

  • Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:3772–3784

    Article  PubMed  Google Scholar 

  • Evelhoch J, Brown T, Chenevert T et al. (2000) Consensus recommendation for acquisition of dynamic contrasted-enhanced MRI data in oncology. Proc Int Soc Magn Reson Med Eighth Scientific Meeting and Exhibition, p 1439

    Google Scholar 

  • Evelhoch J, Lorusso P, Delproposto Z et al. (2002) Dynamic contrast-enhanced MRI evaluation of the effects of ZD6126 on tumor vasculature in a phase I clinical trial. Proc Int Soc Magn Reson Med Tenth Scientific Meeting and Exhibition, p 2095

    Google Scholar 

  • Federal Register (1997) ICH harmonised tripartite guideline for good clinical practice, vol. 62, pp 25691–25709

    Google Scholar 

  • Galbraith SM, Lodge MA, Taylor NJ et al. (2001) Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man, demonstrated by MRI. Proc Amer Soc Clin Oncol 20:278 (abstract)

    Google Scholar 

  • Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826–3840

    Article  PubMed  Google Scholar 

  • Hasan J, Jayson GC (2001) VEGF antagonists. Expert Opin Biol Ther 1:703–718

    PubMed  Google Scholar 

  • Hawighorst H, Knapstein PG, Weikel W, Knopp MV, Zuna I, Knof A, Brix G, Schaeffer U, Wilkens C, Schoenberg SO, Essig M, Vaupel P, van Kaick G (1997) Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 57:4777–4786

    PubMed  Google Scholar 

  • Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, Schönberg SO, Essig M, Vaupel P, van Kaick G (1998) Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 58:3598–3602

    PubMed  Google Scholar 

  • Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schönberg SO, Vaupel P, van Kaick G (1998) Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4:2305–2312

    PubMed  Google Scholar 

  • Hawighorst H, Knapstein PG, Knopp MV, Vaupel P, van Kaick G (1999) Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. MAGMA 8:55–62

    Article  PubMed  Google Scholar 

  • Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792–3803

    Article  PubMed  Google Scholar 

  • Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804–3814

    Article  PubMed  Google Scholar 

  • Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, De Muinck E, Wellens HJ, Kemerink GJ, Reutelingsperger CP, Heidendal GA (2000) Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356:209–212

    Article  PubMed  Google Scholar 

  • Hoskin, P.J., Saunders, M.I., Goodchild, K. et al (1999) Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 72:1093–1098

    PubMed  Google Scholar 

  • Hulka CA, Edmister WB, Smith BL, Tan L, Sgroi DC, Campbell T, Kopans DB, Weisskoff RM (1997) Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837–842

    PubMed  Google Scholar 

  • Ikeda O, Yamashita Y, Morishita S, Kido T, Kitajima M, Okamura K, Fukuda S, Takahashi M (1999) Characterization of breast masses by dynamic enhanced MR imaging. A logistic regression analysis. Acta Radiol 40:585–592

    PubMed  Google Scholar 

  • Jackson A, Haroon H, Zhu XP, Li KL, Thacker NA, Jayson G (2002) Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 15:164–173

    Article  PubMed  Google Scholar 

  • Jackson A, Jayson GC, Li KL, Zhu XP, Checkley DR, Tessier JJ, Waterton JC (2003) Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 76:153–162

    Article  PubMed  Google Scholar 

  • Jayson GC, Zweit J, Jackson A et al. (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484–1493

    PubMed  Google Scholar 

  • Knopp MV, Weiss E, Sinn HP et al. (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260–266

    Article  PubMed  Google Scholar 

  • Kuenen BC, Rosen L, Smit EF et al. (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657–1667

    Article  PubMed  Google Scholar 

  • Leach MO, Brindle KM, Evelhoch JL et al. (2003) Assessment of anti-angiogenic and anti-vascular therapeutics using Magnetic Resonance Imaging: recommendations for appropriate methodology for clinical trials. Proc Int Soc Magn Reson Med Eleventh Scientific Meeting and Exhibition, p 1268

    Google Scholar 

  • Lesko LJ, Atkinson AJ Jr (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347–366

    Article  PubMed  Google Scholar 

  • Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O, Kudo S (2000) Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 217:841–848

    PubMed  Google Scholar 

  • Medved M, Maceneany P, Karxzmar H et al. (2002) Contrast agent dynamics as an early marker of antiangiogenic agent action. Proc Int Soc Magn Reson Med Tenth Scientific Meeting, p 2099

    Google Scholar 

  • Morgan B, Thomas AL, Drevs J et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964

    Article  PubMed  Google Scholar 

  • Nagashima T, Suzuki M, Yagata H et al. (2002) Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast Cancer 9:226–230

    PubMed  Google Scholar 

  • Pradel C, Siauve N, Bruneteau G et al. (2003) Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 21:845–851

    Article  PubMed  Google Scholar 

  • Robinson SP, Mcintyre SJO, Checkley D et al. (2003) Tumour dose response to the anti-vascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88:1592–1597

    Article  PubMed  Google Scholar 

  • Ruehm SG, Christina H, Violas X Corot C, Debatin JF (2002) MR angiography with a new rapid-clearance blood pool agent: Initial experience in rabbits. Magn Reson Med 48:844–851

    PubMed  Google Scholar 

  • Stomper PC, Winston JS, Herman S, Klippenstein DL, Arredondo MA, Blumenson LE (1997) Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 45:39–46

    Article  PubMed  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    PubMed  Google Scholar 

  • Thomas A, Morgan B, Drevs J et al (2001) Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc Amer Soc Clin Oncol 20:abstr 279

    Google Scholar 

  • Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357–367

    PubMed  Google Scholar 

  • Tofts PS, Brix G, Buckley DL et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232

    Article  PubMed  Google Scholar 

  • Tynninen O, Aronen HJ, Ruhala M et al. (1999) MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 34:427–434

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research UK, Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, M20 6DB, UK

    Gordon C. Jayson PhD, FRCP

  2. Enabling Science & Technology, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

    John C. Waterton PhD, FRSC

Authors
  1. Gordon C. Jayson PhD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John C. Waterton PhD, FRSC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Imaging Science and Biomedical Engineering, The Medical School, University of Manchester, Stopford Building Oxford Road, Manchester, M13 9PT, UK

    Alan Jackson MBChB (Hons), PhD, FRCP FRCR (Professor) (Professor)

  2. Imaging Science and Biomedical Engineering, University of Manchester, Stopford Building Oxford Road, Manchester, M13 9PT, UK

    David L. Buckley PhD (Lecturer in Image Science) & Geoffrey J. M. Parker PhD (Research Fellow in Imaging Science) (Lecturer in Image Science) &  (Research Fellow in Imaging Science)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jayson, G.C., Waterton, J.C. (2005). Applications of Dynamic Contrast-Enhanced MRI in Oncology Drug Development. In: Jackson, A., Buckley, D.L., Parker, G.J.M. (eds) Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26420-5_16

Download citation

  • DOI: https://doi.org/10.1007/3-540-26420-5_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-42322-5

  • Online ISBN: 978-3-540-26420-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation